Li et al., in their 2013 study, noted the potential of NK-HDAC-1, an HDAC inhibitor, as a therapeutic avenue for CIA and pathogenic FLSs obtained from individuals affected by RA. This evidence concerns the gene HDAC9 and rheumatoid arthritis.